Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the levels of regional variation in the provision of radioligand therapy across England.

No specific assessment has been made.

Where treatments, such as radioligand, are approved via the National Institute for Health and Care Excellence’s technology appraisals, NHS England seek to ensure appropriate access for patients within the license of the treatment. NHS England is appointing a new National Specialty Advisor for Nuclear Medicine to ensure the opportunities for approved radioligand therapies are realised.